A novel multicomponent vaccine combining seasonal influenza and COVID-19 antigens has shown promising safety and immune responses in adults. The vaccine, mRNA-1073, integrates antigens from authorized mRNA influenza and COVID-19 vaccines into a single dose, aiming to simplify immunization schedules.
The phase 1/2 clinical trial enrolled 550 healthy adults aged 18 to 75. Participants received varying doses of mRNA-1073, individual vaccines, or a combination. The study reported mild to moderate side effects, with no severe vaccine-related events or deaths. Reactogenicity increased with dose but remained within acceptable limits, supporting the vaccine's safety.
Immunogenicity analysis revealed that a single dose of mRNA-1073 elicited strong and durable antibody responses against all matched influenza and COVID-19 strains. Systems serology profiling showed balanced immune responses comparable to receiving separate vaccines, indicating no compromise in immune efficacy. Antibody responses persisted for six months, suggesting long-term protection.
This single-dose, multicomponent mRNA vaccine could streamline vaccination campaigns and increase uptake. While further studies are needed to confirm efficacy in larger, diverse populations, the findings support research into mRNA vaccines targeting multiple respiratory pathogens simultaneously.